Literature DB >> 26444633

CD47 blockade as another immune checkpoint therapy for cancer.

Robert H Vonderheide1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26444633     DOI： 10.1038/nm.3965

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  36 in total

Review 1.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

Review 2.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

3.  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.

Authors:  Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Liang Mao; Lei-Lei Yang; Si-Rui Ma; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

4.  Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway.

Authors:  Zhi Qiao; Yan Zhang; Maolin Ge; Sha Liu; Xiaoteng Jiang; Zhi Shang; Han Liu; Chengxi Cao; Hua Xiao
Journal:  Mol Cell Proteomics       Date:  2019-06-13       Impact factor: 5.911

5.  Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma.

Authors:  B López-Pereira; A A Fernández-Velasco; I Fernández-Vega; D Corte-Torres; C Quirós; J A Villegas; P Palomo; S González; A P González; Á Payer; T Bernal; M A Moro-García; R Alonso-Arias; S Alonso-Álvarez; E Colado
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

6.  Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.

Authors:  Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  EMBO Mol Med       Date:  2021-02-15       Impact factor: 12.137

7.  The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.

Authors:  Oleg Kruglov; Lisa D S Johnson; Angela Minic; Kimberly Jordan; Robert A Uger; Mark Wong; Eric L Sievers; Yaping Shou; Oleg E Akilov
Journal:  Cancer Immunol Immunother       Date:  2021-09-14       Impact factor: 6.968

8.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.

Authors:  Anthony L Schwartz; Pulak R Nath; Michael Allgauer; Elizabeth C Lessey-Morillon; John M Sipes; Lisa A Ridnour; Y Maurice Morillon Ii; Zhiya Yu; Nicholas P Restifo; David D Roberts
Journal:  Cancer Immunol Immunother       Date:  2019-10-18       Impact factor: 6.968

9.  Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.

Authors:  Yoonjeong Choi; Gi-Hoon Nam; Gi Beom Kim; Seohyun Kim; Yoon Kyoung Kim; Seong A Kim; Ha-Jeong Kim; Eun Jung Lee; In-San Kim
Journal:  Cancer Gene Ther       Date:  2021-08-04       Impact factor: 5.987

10.  Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.

Authors:  Haiqing Ni; Lei Cao; Zhihai Wu; Li Wang; Shuaixiang Zhou; Xiaoli Guo; Yarong Gao; Hua Jing; Min Wu; Yang Liu; Jiazheng Ding; Pan Zhang; Ying Zhou; Bingliang Chen; Yao Xiong; Jiya Sun; Bianka Prinz; Hemanta Baruah; James Geoghegan; Michael Yu; Weiwei Wu; Junjian Liu
Journal:  Cancer Immunol Immunother       Date:  2021-06-24       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.